Oligonucleotides moving from rare drug provision to wider population usage can be underpinned by affordable phosphoramidite provision. A bold statement becomes real with the 2021 approval of Inclisiran, used for the treatment of cardiovascular disease. A breadth of common diseases, including cardiovascular disease, oncology and metabolic disorders will respond to Oligonucleotide drug provision. Oligonucleotides because […]
We look forward to attending TIDES in November. It’s the industry’s leading event to accelerate therapeutics to market by expediting R&D, improving CMC efficiency, and building new partnerships. We hope to see you all there.